Comparative Effectiveness of Therapies for Reducing the Risk of Primary Breast Cancer: Guidance for Shared Decision Making- Breast cancer is the most commonly diagnosed noncutaneous cancer among women in the United States. In 2010, more than 200,000 cases of invasive breast cancer were diagnosed, and nearly 40,000 women died from the disease. For women considered to be at high risk for primary breast cancer, leading oncology organizations have endorsed risk-reducing therapies. The options include tamoxifen and raloxifene, which are FDA approved for preventive use in selected groups of at-risk women and tibolone, which is not currently FDA approved. Clinical trials have demonstrated that all 3 medications significantly reduce the risk of developing the disease in women without pre-existing cancer. The trials have also indicated the nature and magnitude of harms associated with the 3 medications.Toward the goal of informed and shared decision making, this patient-centered educational program guides clinicians in discussing AHRQ's findings with women who may be candidates for FDA-approved therapies for reducing the risk of primary breast cancer.
Compare the effectiveness of tamoxifen, raloxifene, and tibolone in the general population and specific subpopulations of at-risk women. Evaluate key differences in side effects, harms, persistence, and adherence associated with tamoxifen, raloxifene, and tibolone. Apply the findings in clinical settings to help at-risk women make informed and shared decisions about whether to use risk-reducing medications.
1 .0 Contact Hour for Nurse Practitioners which includes 0.25 hours of pharmacology
Expires 10/14/14
